Speech-Language Pathologists in Neligh, NE Accepting Medicare

9 Speech-Language Pathologists found. Showing 1 - 9

Mary Jo Benson Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 302 Main St, Neligh, NE 68756 Phone: 402-887-5041

Sheila Kropp Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 302 Main St, Neligh, NE 68756 Phone: 402-887-5041

Sherry Aufdenkamp Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 302 Main St, Neligh, NE 68756 Phone: 402-887-5041

Mrs. Andrea Petersen Mcgregor, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 302 Main St, Neligh, NE 68756 Phone: 402-887-5041

Chloe Strong Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 110 W 3rd St, Neligh, NE 68756 Phone: 402-887-5041    Fax: 866-737-5735

Tricia Spieker Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 302 Main St, Neligh, NE 68756 Phone: 402-887-5041

Shawn Dilly Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1100 N St, Neligh, NE 68756 Phone: 402-887-5428

Miss Sarah Hake, M.S., CCC-SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: Educational Service Unit #8, 110 W 3rd St, Neligh, NE 68756 Phone: 402-887-5041

Mrs. Lindsey Albrecht, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 302 Main Street, Neligh, NE 68756 Phone: 402-887-5041    Fax: 402-887-4604

News Archive

Hospitals to receive payments from Medicare and Medicaid for effective use of EHRs

According to a survey released today by CSC titled "Are Hospitals Ready for Meaningful Use of EHRs?" U.S. hospitals are only halfway to qualifying for government incentive payments aimed at controlling healthcare costs while improving the quality and effective delivery of patient care.

Medicago launches clinical development of seasonal flu vaccine

Medicago Inc. a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that the first dose of vaccine has been administered thereby initiating the Company's phase I H1N1 influenza VLP vaccine candidate ("H1N1 vaccine") clinical trial in the United States. The primary safety and immunogenicity results for this trial are expected within three months.

Simulation-based training helps doctors deliver bad news more effectively to patients

We've all feared hearing a doctor say, "We need to talk." It's even scarier if the physician is robotic, speaks in jargon or isn't clear about next steps.

New protocol to deliver optimal care for breastfeeding women with breast cancer

Managing women with breast cancer who are breastfeeding is a complex issue. The Academy of Breastfeeding Medicine presents new recommendations in the peer-reviewed journal Breastfeeding Medicine.

Read more Medical News

› Verified 1 days ago